First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yhim, Ho-Young | - |
dc.contributor.author | Yoon, Dok Hyun | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Yang, Deok-Hwan | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Ha Kim, Kyoung | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.contributor.author | Kim, Won Seog | - |
dc.contributor.author | Kwak, Jae-Yong | - |
dc.date.accessioned | 2021-08-30T18:36:55Z | - |
dc.date.available | 2021-08-30T18:36:55Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/54248 | - |
dc.description.abstract | There are limited data from prospective controlled trials regarding optimal treatment strategies in patients with primary breast diffuse large B-cell lymphoma (DLBCL). In this phase 2 study (NCT01448096), we examined the efficacy and safety of standard immunochemotherapy and central nervous system (CNS) prophylaxis using intrathecal methotrexate (IT-MTX). Thirty-three patients with newly diagnosed primary breast DLBCL received six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and four fixed doses of IT-MTX (12 mg). The median age was 50 years (range, 29-75), and all patients were females. According to the CNS-International Prognostic Index, most patients (n= 28) were categorized as the low-risk group. Among the 33 patients, 32 completed R-CHOP, and 31 completed IT-MTX as planned. With a median follow-up of 46.1 months (interquartile range (IQR), 31.1-66.8), the 2-year progression-free and overall survival rates were 81.3% and 93.5%, respectively. Six patients experienced treatment failures, which included the CNS in four patients (two parenchyma and two leptomeninges) and breast in two patients (one ipsilateral and one contralateral). The 2-year cumulative incidence of CNS relapse was 12.5%. Although standard R-CHOP and IT-MTX without routine radiotherapy show clinically meaningful survival outcomes, this strategy may not be optimal for reducing CNS relapse and warrants further investigation. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | CNS PROPHYLAXIS | - |
dc.subject | RITUXIMAB | - |
dc.subject | OUTCOMES | - |
dc.subject | IMPACT | - |
dc.subject | RISK | - |
dc.subject | IBRUTINIB | - |
dc.title | First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.identifier.doi | 10.3390/cancers12082192 | - |
dc.identifier.scopusid | 2-s2.0-85090621234 | - |
dc.identifier.wosid | 000578999500001 | - |
dc.identifier.bibliographicCitation | CANCERS, v.12, no.8 | - |
dc.relation.isPartOf | CANCERS | - |
dc.citation.title | CANCERS | - |
dc.citation.volume | 12 | - |
dc.citation.number | 8 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | CNS PROPHYLAXIS | - |
dc.subject.keywordPlus | RITUXIMAB | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | IBRUTINIB | - |
dc.subject.keywordAuthor | central nervous system | - |
dc.subject.keywordAuthor | diffuse large B-cell lymphoma | - |
dc.subject.keywordAuthor | primary breast lymphoma | - |
dc.subject.keywordAuthor | prophylaxis | - |
dc.subject.keywordAuthor | rituximab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.